<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552067</url>
  </required_header>
  <id_info>
    <org_study_id>Enoxaparine</org_study_id>
    <nct_id>NCT04552067</nct_id>
  </id_info>
  <brief_title>Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients</brief_title>
  <acronym>Enoxaparine</acronym>
  <official_title>Generic and Branded Enoxaparin Bioequivalence: a Randomized Study in Acute Coronary Syndrome Patients With an In-vitro Thrombin Generation Testing Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of their anti-Xa and ease of administration activity, the Low molecular weight&#xD;
      heparin represent an attractive alternative to the unfractionated heparin. Several clinical&#xD;
      trials have demonstrated that Low molecular weight heparin was more effective than&#xD;
      Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the&#xD;
      most studied. Its use is recommended.&#xD;
&#xD;
      Demonstrate that Enoxa® is comparable to that of Lovenox® in the anti-Xa activity action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center randomized controlled trial, single-blind, including patient with an acute&#xD;
      coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was&#xD;
      done on two groups ; ENOXA® group : In this case the patient is given an injection of&#xD;
      enoxaparin ( ENOXA® ; UNIMED Laboratories) intravenously. Curative dose (100 IU/10 kg).&#xD;
&#xD;
      Control group ( LOVENOX ® ):&#xD;
&#xD;
      In this case the patient receives LOVENOX intravenous injection curative dose of 100 kg IU/10&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti Xa activity (UI/ml)</measure>
    <time_frame>4 hours</time_frame>
    <description>Compare the Anticoagulant Activity (measured in a UI per ml in a reference laboratory) of Two Formulations of Enoxaparin [ENOXA ® Versus LOVENOX ®], Conducted on Two Parallel Groups of Patients Admitted to Emergency for Acute Coronary Syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>30 days</time_frame>
    <description>All major cardiovascular events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>LOVENOX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients are given a curative dose of Enoxaparin (LOVENOX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxamed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients are given a curative dose of Enoxaparin (ENOXA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovenox</intervention_name>
    <description>patients given curative dose of Lovenox</description>
    <arm_group_label>LOVENOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>patients given curative dose of Enoxa</description>
    <arm_group_label>Enoxamed</arm_group_label>
    <other_name>Enoxamed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 year old&#xD;
&#xD;
          -  With an acute coronary syndrome confirmed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Persistent ST segment elevation&#xD;
&#xD;
          -  Contre indication of enoxaparin and heparin in general.&#xD;
&#xD;
          -  Patient participating in another study,&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  patients taking an anticoagulant in the last three months,&#xD;
&#xD;
          -  Patients with coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nouira Semir, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency Department of University Hospital of Monastir</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://www.urgencemonastir.com</url>
    <description>official website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Pr. Semir Nouira</investigator_full_name>
    <investigator_title>Head of departement</investigator_title>
  </responsible_party>
  <keyword>enoxaparin</keyword>
  <keyword>Lovenox</keyword>
  <keyword>ani-Xa</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>Enoxa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

